METHYS Dx Expands Access to its M*Detect kits for digital PCR Across Europe and North America with Distribution Agreement with CliniSciences
Paris, 01/12/2025. METHYS Dx, a company with pioneering liquid biopsy solutions based on methylation signatures, announced today it had entered into a distribution agreement with CliniSciences. This agreement will enable the large-scale commercialization of METHYS Dx M*Detect kits for digital PCR in RUO (Research Use Only) format across Europe, North America and North Africa.
METHYS Dx currently commercializes five kits for clinical research, each dedicated to a specific cancer type: pancreatic cancer, colorectal cancer, gastric cancer, lung cancer and endometrial cancer. These kits, compatible with existing digital PCR instruments, enable precise and fast quantification of circulating tumor DNA for near real-time tracking of tumor evolution. CliniSciences will manage the distribution of the M*Detect range in 19 countries across Europe, the United States and Morocco. This agreement is a key lever to strengthen the international visibility of the M*Detect solutions, accelerate the adoption of the kits by translational oncology research laboratories, and prepare the path toward future clinical applications (beyond RUO), thanks to broader deployment and the valuable feedback it will generate.
“We are delighted to partner with Clinisciences, commented Magali Droniou, METHYS Dx COO. For METHYS Dx, this partnership represents a strategic opportunity to expand access to our M*Detect kits for digital PCR across key markets. Clinisciences is a very strong partner with an established customer base. We look forward to work alongside their team of technical experts to make accessible our innovative liquid biopsy tools for clinicians, researchers and pathologists, and effectively support customers on a global scale.”
“The collaboration with Methys Dx is fully aligned with our strategic vision to expand our portfolio in precision oncology. Their cutting-edge molecular diagnostic solutions complement our commitment to delivering innovative, high clinical value tools to laboratories and clinicians across Europe.”
— Tushendan Rasiah, CEO of CliniSciences Group
About METHYS Dx
METHYS Dx develops innovative liquid biopsy tests for non-invasive monitoring of cancer patients. Combining unique proprietary molecular signatures with digital PCR, METHYS Dx tests allow monitoring of tumor evolution and will thus improve patient care through better-informed therapeutic decisions.
Incorporated in 2021 and based in Paris, France, METHYS Dx originates from more than 10 years of fruitful collaboration between 2 internationally renowned teams with complementary expertises: the MEPPOT team (Personalized Medicine, Pharmacogenomics and therapeutic optimization, Cordeliers research center, Univ. Paris Cité/ Sorbonne Université/ INSERM), with expertise in oncology, translational research and biomarker discovery, and the SPM team (system and molecular programming, Gulliver laboratory, ESPCI, CNRS/ PSL) with expertise in technology development and its application to human health challenges.
About Clinisciences
CliniSciences is a European group specializing in the distribution and manufacture of reagents and equipment for scientific research and clinical diagnostics. With over 40 years of experience in oncology diagnostics, the group offers a comprehensive portfolio of high-quality in vitro diagnostic products, developed in collaboration with renowned international partners.
Operating in 19 countries through a network of more than 130 employees, the majority of whom are PhD-level scientists, CliniSciences supports a customer base of over 350,000 researchers and clinicians. The group’s mission is to accelerate scientific innovation by actively promoting technologies and discoveries from academic and clinical laboratories, particularly in the field of cancer diagnostics and precision medicine.
CliniSciences continues to invest in expertise, quality, and partnerships to deliver trusted solutions that meet the evolving needs of the scientific and medical communities across Europe and beyond.